文献速递妇科生殖医学

左炔诺孕酮宫内系统与口服甲羟孕酮在不典型子宫内膜增生不孕患者中的比较

Levonorgestrel-releasing intrauterine system versus oral medroxyprogesterone acetate in infertile women with endometrial hyperplasia without atypia.
PubMed 文献 · Reprod Biomed Online · 2021-08-30

这项前瞻性队列研究纳入215例患有不典型子宫内膜增生且需辅助生殖的不孕女性,比较左炔诺孕酮宫内系统(LNG-IUS)与口服甲羟孕酮(MPA)对子宫内膜增生逆转及妊娠率的影响。结果显示LNG-IUS组首次随访逆转率更高(100% vs 58.8%,P<0.001),但二线治疗后逆转率、临床妊娠率、流产率及累积活产率两组相似。结论认为LNG-IUS不损害不孕患者的妊娠机会。

要点

  • LNG-IUS组首次随访增生逆转率显著高于口服MPA组(100% vs 58.8%,P<0.001)。
  • 二线治疗后两组逆转率相似(97.8% vs 98.4%,P=0.22)。
  • 辅助生殖后临床妊娠率、流产率及累积活产率两组无显著差异。

核心结论

  • LNG-IUS较口服MPA能提高不典型子宫内膜增生不孕患者的首次随访逆转率,但辅助生殖后的活产率两组相当,且LNG-IUS不损害妊娠机会。

研究设计与样本

  • 前瞻性队列研究,纳入215例需辅助生殖技术且诊断为不典型子宫内膜增生的不孕女性,比较LNG-IUS与口服MPA(10mg每日)的疗效。

主要发现

  • 首次随访逆转率LNG-IUS组28/28(100%),口服孕激素组110/187(58.8%),P<0.001。
  • 二线治疗后逆转率LNG-IUS组89/91(97.8%),口服MPA组122/124(98.4%),P=0.22。
  • 辅助生殖后临床妊娠率LNG-IUS组34% vs 口服MPA组39.5%,流产率22.6% vs 34.7%,累积活产率26.4% vs 25.8%。

关键数值与推荐

  • 口服MPA剂量为10mg每日,LNG-IUS为宫内系统。
  • 随访活检安排在治疗90天后。
  • 增生逆转后进入IVF/ICSI周期。

临床怎么用

  • 对于不典型子宫内膜增生的不孕患者,LNG-IUS可作为口服MPA的替代选择,尤其希望快速逆转者,且不影响后续辅助生殖的妊娠结局。

局限性

  • 本研究为前瞻性队列研究,非随机对照,可能存在残余混杂,尽管使用了倾向评分加权。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: How does use of a levonorgestrel-releasing intrauterine system (LNG-IUS) in infertile women with endometrial hyperplasia without atypia affect endometrial hyperplasia regression and pregnancy rates compared with oral medroxyprogesterone acetate (MPA)? DESIGN: This prospective cohort study included 215 infertile women with an indication for assisted reproductive technology (ART) and a diagnosis of endometrial hyperplasia without atypia. Endometrial hyperplasia was diagnosed by hysteroscopic endometrial biopsy. At the time of first- and second-line treatment, patients were offered therapy with either oral MPA 10 mg daily or LNG-IUS. Follow-up biopsies were scheduled after 90 days' treatment. After endometrial hyperplasia regression, patients were admitted to IVF/intracytoplasmic sperm injection (ICSI) cycles. RESULTS: Baseline characteristics and confounders including age at diagnosis, body mass index and duration of infertility did not differ between LNG-IUS users and control participants and were accounted for using propensity score weighting. Endometrial hyperplasia regression rate at first follow-up was higher in the LNG-IUS group than the oral progestins group (28/28, 100% and 110/187, 58.8%; P < 0.001), while that after second-line treatment was comparable between the two groups (89/91, 97.8% and 122/124, 98.4%; P = 0.22). Clinical pregnancy rate, miscarriage rate and cumulative live birth rate following ART in patients ever receiving LNG-IUS were similar to those of patients receiving only MPA (34% versus 39.5%, 22.6% versus 34.7% and 26.4% versus 25.8%). CONCLUSION: Endometrial hyperplasia regression is greater in women receiving LNG-IUS compared with oral MPA, while live birth rates following ART are comparable between the two groups. The use of LNG-IUS does not jeopardize the chances of pregnancy in women seeking fertility treatment.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Campo G, Rebecchi A, Vanni VS, et al. Levonorgestrel-releasing intrauterine system versus oral medroxyprogesterone acetate in infertile women with endometrial hyperplasia without atypia. Reprod Biomed Online. 2021. PMID: 34629315. doi:10.1016/j.rbmo.2021.08.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。